Frontiers in the search for new antimicrobials: new perspectives
DOI:
https://doi.org/10.34117/bjdv9n6-148Keywords:
Fungi, Candida, treatmentAbstract
Infections caused by bacteria and fungi resistant to antimicrobials are one of the main public health problems in the world. These microorganisms are associated with high rates of morbidity and mortality and also with high hospital costs. Their emergence and spread are closely related to the excessive and inappropriate use of antimicrobials in medical and veterinary practices and in animal production. For the treatment of Candida spp. there are few classes of antifungals available for treatment, the classes being: azole derivatives, polyenes and echinocandins. The class of azoles includes imidazole derivatives (ketoconazole, miconazole, clotrimazole), triazole derivatives (fluconazole, itraconazole and voriconazole) and posaconazole. These drugs can be used for topical us as well as in the treatment and prophylaxis of invasive infections. The wide use of these drugs has led to a strong selection of strains resistant to them, which is increasingly growing. The need to produce new antimicrobial drugs requires different strategies, among which we highlight the importance of bioprospecting for secondary metabolites of environmental bacteria and fungi with potential antimicrobial activity.
References
WHO. World Health Organization http://www.who.int/mediacentre/factsheets/fs337/en/ (Accessed May 5, 2022).
Wattal, C.; Goel, N. Pediatric Blood Cultures and Antibiotic Resistance: An Overview. Indian J Pediatr., 2020, 87(2):125-131.
Linares-Otoya, L.; Linares- Otoya , V.; Armas‐Mantilla, L.; Blanco-Olano, C.; Crusemann, M.; Ganoza‐Yupanqui, M.L.; Schaberle, T.F. Diversity and antimicrobial potential of predatory bacteria from the Peruvian Coastline. Mar Drugs, 2017, 15(10):1-14.
Wencewicz T.A. Crossroads of Antibiotic Resistance and Biosynthesis. J Mol Biol., 2019, 3(18):3370-3399.
Paul, M.; Carrara, E.; Retamar, P.; Tängdén, T.; Bitterman, R.; Bonomo, R.A.; Waele J.; Daikos G.L.; Akova, M.; Harbarth, S.; Pulcini, C.; Garnacho-Montero, J.; Seme, K.; Tumbarello, M.; Lindemann, P.C.; Gandra, S.; Yu, Y.; Bassett, M.; Mouton, J.W.; Tacconelli, E.; Rodríguez-Baño, J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect., 2022, 28(4):521-547.
Fisher, R.A.; Gollan B.; Helaine S. Persistent bacterial infections and persister cells. Nat Rev Microbiol., 2017, 5(8):453-464.
Sekyere J.O.; Asante J. Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in the era of genomics. Future Microbiol., 2018, 13:241-262.
Lamoth F.; Lockhart, S.R.; Berkow, E.L.; Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother., 2018,3(1): i4–i13.
Berman, J.; Krysan, D.J. Drug resistance and tolerance in fungi. Nat Rev Microbiol., 2020, 8(6):319-331.
Duzgol. M.; Boncuoglu, E.; Kiymet, E.; Akaslan Kara, A.; Erdem, M.; Odaman Al, I.; Demirag, B.; Zihni, C.; Hilkay Karapinar, T.; Oymak, Y.; Mese, T.; Bayram. N.; Devrim, I. Evaluation for Metastatic Candida Focus and Mortality at Candida-associated Catheter-related Bloodstream Infections at the Pediatric Hematology-oncology Patients. J Pediatr Hematol Oncol., 2022, 44(3):e643-e648.
Vinayagamoorthy, K.; Pentapati, K.C.; Prakash, H. Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review. Mycoses., 2022,65(6):613-624.
Dahiya, S.; Sharma, N.; Punia, A.; Choudhary, P.; Gulia P.; Parmar, V.S.; Chhillar, A.K. Antimycotic Drugs and their Mechanisms of Resistance to Candida Species. Curr Drug Targets., 2022; 23(2):116-125.
Bondaryk, M.; Kurzątkowski, W.; Staniszewska, M. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. Postepy Dermatol Alergol., 2013, 30(5):293-301.
Ruiz-Gaitán, A.; Del Pozo, J.L. AmBisome, three challenges: Candida auris infection, central nervous system infection, and biofilm-associated infection. Rev Iberoam Micol., 2021, 38(2):84-90.
Li, J.; Jin, Z.H.; Li, J.S.; Su, L.Y.; Wang, Y.X.; Zhang, Y.; Qin, D.M.; Rao, G.X.; Wang, R.R. Activity of Compound Agrimony Enteritis Capsules against invasive candidiasis: Exploring the differences between traditional Chinese medicine prescriptions and its main components in the treatment of diseases. J Ethnopharmacol., 2021,15: 114201.
Mba, I.E.; Nweze, E.I. Mechanism of Candida pathogenesis: revisiting the vital drivers. Eur J Clin Microbiol Infect Dis., 2020, 39(10):1797-1819.
Matthew I.H.; Andrew, W.; Truman, B.W. Antibiotics: past, present and future. Curr Opin Microbiol., 2019,51:72-80.
Durand, G.A.; Raoult, D.; Dubourg, G. Antibiotic discovery: history, methods and perspectives. Int J Antimicrob Agents., 2019, 53(4):371-382.
Lobanovska, M.; Pilla, G. Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future? Yale. J Biol Med., 2017, 29; 90(1):135-145.
Browne, K.; Chakraborty, S.; Chen, R.; Willcox, M.D.; Black, D.S.; Walsh, W.R.; Kumar, N. A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides. Int J Mol Sci., 2020, 24;21(19):7047
Baltz, R. H. Natural Product Drug Discovery in the Genomic Era: Realities, Conjectures, Misconceptions, and Opportunities. J. Ind. Microbiol. Biotechnol., 2019, 46(4): 281–299.
Jakubiec-Krzesniak, K.; Rajnisz-Mateusiak, A.; Guspiel, A.; Ziemska, J.; Solecka, J. Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties. Pol J Microbiol., 2018, 67(3):259-272.
Katz, L.; Baltz, R.H. Natural Product Discovery: Past, Present, and Future. J. Ind. Microbiol. Biotechnol., 2016, 43 (2–3), 155–176.
Saldívar-González, F.I.; Aldas-Bulos, V.D.; Medina-Franco, J.L.; Plisson, F. Natural product drug discovery in the artificial intelligence era. Chem Sci., 2021,13(6):1526-1546.
Boparai, J.K.; Sharma, P.K. Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications. Protein Pept Lett., 2020, 27(1):4-16.
Bao, Y.; Li, H.; Dong, Y.; Duan, H.; Li, H.; Li, W. Genome-Guided Discovery of Antifungal Filipins from a Deep-Sea-Derived Streptomyces Antibioticus. J. Nat. Prod., 2022, 85(2):365-374.
Wang, P.; Wang, D.; Zhang, R.; Wang, Y.; Kong, F.; Fu, P.; Zhu, W. Novel Macrolactams from a Deep-Sea-Derived Streptomyces Species. Mar Drugs., 2020, 29;19(1):13.
Chan-Bacab, M.J.; Reyes-Estebanez, M.M.; Camacho-Chab, J.C.; Ortega-Morales, B.O. Microorganisms as a Potential Source of Molecules to Control Trypanosomatid Diseases. Mol. Basel Switz., 2021, 26 (5), 1388.
Girão, M,. Ribeiro, I.; Ribeiro, T.; Azevedo, I.C.; Pereira, F.; Urbatzka, R.; Leão, P.N.; Carvalho, M.F. Actinobacteria Isolated From Laminaria ochroleuca: A Source of New Bioactive Compounds. Front Microbiol., 2019, 10:683.
Mehravar, M.; Sardari, S.; Owlia P. Membrane-active metabolites produced by soil actinomycetes using chromatic phospholipid/polydiacetylene vesicles. Indian J Exp Biol. 2011, 49(12):946-952.
Kautsar, S.A.; Blin, K.; Shaw, S.; Weber, T.; Medema, M. H. BiG-FAM: The Biosynthetic Gene Cluster Families Database. Nucleic Acids Res., 2020, 49: 490–497.
Takahashi, Y. Continuing fascination of exploration in natural substances from microorganisms. Biosci Biotechnol Biochem., 2017;81(1):6-12.
Hou, X.M.; Hai, Y.; Gu, Y.C.; Wang, C.Y.; Shao, C.L. Chemical and Bioactive Marine Natural Products of Coral-Derived Microorganisms (2015-2017). Curr Med Chem., 2019, 26(38):6930-6941.
Alizadeh-Sani, M.; Hamishehkar, H.; Khezerlou, A. Bioemulsifiers Derived from Microorganisms: Applications in the Drug and Food Industry. Adv Pharm Bull., 2018, 8(2):191-199.
